Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 2/20 | 0.56 |
| ▸ | KIT | P10721 | 2/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.56 |
| ▸ | CDK11B | P21127 | 1/20 | 0.56 |
| ▸ | FLT3 | P36888 | 1/20 | 0.56 |
| ▸ | CDKL2 | Q92772 | 1/20 | 0.56 |
| ▸ | BRAF | P15056 | 9/20 | 0.45 |
| ▸ | KDR | P35968 | 9/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.45 |
| ▸ | TNNI3K | Q59H18 | 6/20 | 0.45 |
| ▸ | RAF1 | P04049 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | FLT4 | P35916 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12348812 | 0.91 | PDGFRB (0.48) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL12336248 | 0.88 | KDR (0.47) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL625598 | 0.88 | PDGFRB (0.73) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL12336274 | 0.87 | BRAF (0.45) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL12336512 | 0.86 | KDR (0.51) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL12336756 | 0.86 | PDGFRB (0.59) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL14949596 | 0.86 | BRAF (0.45) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL14949582 | 0.85 | KDR (0.44) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL14949574 | 0.85 | BRAF (0.44) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL14949590 | 0.85 | KDR (0.43) | PDGFRBKITPDGFRACDK11BFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130266636-A1 | METHODS FOR BLOCKING CELL PROLIFERATION AND TREATING DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-10 | — | — | US | claimed |
| WO-2012021778-A2 | METHODS FOR BLOCKING CELL PROLIFERATION AND TREATING DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-16 | — | — | WO | claimed |
| US-20160237064-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ALLOSTERIC KINASE INHIBITION | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2016-08-18 | — | — | US | disclosed |
| US-9260417-B2 | Therapeutic methods and compositions involving allosteric kinase inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20140296268-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ALLOSTERIC KINASE INHIBITION | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2014-10-02 | — | — | US | disclosed |
| US-20130266636-A1 | METHODS FOR BLOCKING CELL PROLIFERATION AND TREATING DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-10 | — | — | US | disclosed |
| WO-2012021778-A2 | METHODS FOR BLOCKING CELL PROLIFERATION AND TREATING DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-16 | — | — | WO | disclosed |
| WO-2011097594-A2 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ALLOSTERIC KINASE INHIBITION | KINAGEN, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237064-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ALLOSTERIC KINASE INHIBITION | TIE1, PRKCH, PACSIN2 | PDGFRB 486/4885KIT 799/4885PDGFRA 644/4885 |
| US-20140296268-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ALLOSTERIC KINASE INHIBITION | TIE1, PRKCH, PACSIN2 | PDGFRB 486/4885KIT 799/4885PDGFRA 644/4885 |
| US-20130266636-A1 | METHODS FOR BLOCKING CELL PROLIFERATION AND TREATING DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION | BRAF, BUB1B, MKI67 | PDGFRB 1405/4885KIT 1806/4885PDGFRA 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.